MASLD VCTE-C cohort: a prospective multicenter study linking liver fibrosis to cardiovascular outcomes in patients with metabolic dysfunction–associated steatotic liver disease
11 affiliations
- 1Department of Internal Medicine, Soonchunhyang University Seoul Hospital, Soonchunhyang University College of Medicine
- 2Department of Internal Medicine, Korea University Ansan Hospital
- 3Department of Internal Medicine, Chung-Ang University Hospital
- 4Center for Liver and Pancreatobiliary Cancer, National Cancer Center
- 5Department of Internal Medicine, Seoul St. Mary’s Hospital, The Catholic University of Korea
- 6Department of Internal Medicine, Seoul National University Hospital
- 7Department of Internal Medicine, Kyungpook National University Hospital
- 8Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine
- 9Department of Internal Medicine, Soonchunhyang University Bucheon Hospital
- 10Department of Internal Medicine, Hanyang University Hospital
- 11Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine
Abstract
Background: Metabolic dysfunction–associated steatotic liver disease (MASLD) is associated with increased risk of cardiovascular disease (CVD). The MASLD vibration-controlled transient elastography (VCTE)-C cohort is designed to examine the relationships among VCTE-derived hepatic measures, coronary artery calcification, and long-term cardiovascular outcomes in patients with MASLD.
Methods: This prospective, multicenter observational cohort will enroll 880 patients with VCTE-defined MASLD (controlled attenuation parameter [CAP] ≥248 dB/m) across 11 tertiary hospitals in the Republic of Korea. Additional eligibility criteria include at least one of the following: (i) type 2 diabetes; (ii) prediabetes; or (iii) obesity accompanied by at least one additional cardiovascular risk factor. Baseline assessments include noninvasive surrogates for liver fibrosis (fibrosis-4 index and liver stiffness measurement by VCTE) and steatosis (CAP by VCTE), coronary artery calcium scoring by noncontrast cardiac computed tomography, cardiometabolic profiling, and 10-year cardiovascular risk estimation primarily using the PREVENT equations, with the Pooled Cohort Equations and K-CVD model applied as complementary tools.
Outcomes: The primary outcome is time to the first occurrence of a four-component major adverse cardiovascular event, comprising acute myocardial infarction, stroke, cardiovascular death, or coronary revascularization. Secondary outcomes include other cardiovascular events, hepatic and renal outcomes, extrahepatic malignancy, and all-cause mortality. Participants will be followed for up to 10 years with serial VCTE; repeat coronary artery calcium scoring is planned at 5 and 10 years in eligible participants.
Conclusion: The MASLD VCTE-C cohort is expected to provide prospective evidence on liver–cardiovascular relationships that may inform integrated risk assessment in patients with MASLD. (KCT0012473).
Related
- Comparative Efficacy and Safety of Saroglitazar and Dapagliflozin on Hepatic Steatosis and Glycemic Control in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease: A 25-Week Prospective Multicenter Comparative Cohort Study.
- Cumulative estimated glucose disposal rate and longitudinal eGDR patterns in relation to incident cardiovascular disease among middle-aged and older adults with metabolic dysfunction-associated steatotic liver disease: a prospective cohort study
- Metabolic and Renal Dysfunction Are Associated With Intraplaque Lipid Burden Assessed by Near‐Infrared Spectroscopy Intravascular Ultrasound: Insights Into the Cardiovascular–Kidney–Metabolic Axis
- Risk assessment of cardiovascular disease-related mortality in metabolic dysfunction-associated steatotic liver disease
- Dose-dependent efficacy and renal safety of pemafibrate versus fenofibrate in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and hypertriglyceridemia: a multicenter randomized controlled, open label trial
BibTeX
@article{chang2026masld,
title = {{MASLD VCTE-C cohort: a prospective multicenter study linking liver fibrosis to cardiovascular outcomes in patients with metabolic dysfunction–associated steatotic liver disease}},
author = {Young Chang and Young Kul Jung and Han Ah Lee and Yuri Cho and Ji Won Han and Su Jong Yu and Soo Young Park and Won-Mook Choi and Sang Gyune Kim and Dae Won Jun and Seung Up Kim},
journal = {Frontiers in Endocrinology},
year = {2026},
month = nov,
doi = {10.3389/fendo.2026.1976585},
url = {https://www.frontiersin.org/articles/10.3389/fendo.2026.1976585/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - MASLD VCTE-C cohort: a prospective multicenter study linking liver fibrosis to cardiovascular outcomes in patients with metabolic dysfunction–associated steatotic liver disease
AU - Young Chang
AU - Young Kul Jung
AU - Han Ah Lee
AU - Yuri Cho
AU - Ji Won Han
AU - Su Jong Yu
AU - Soo Young Park
AU - Won-Mook Choi
AU - Sang Gyune Kim
AU - Dae Won Jun
AU - Seung Up Kim
PY - 2026
DA - 2026/11/12
JO - Frontiers in Endocrinology
DO - 10.3389/fendo.2026.1976585
UR - https://www.frontiersin.org/articles/10.3389/fendo.2026.1976585/full
AB - Background: Metabolic dysfunction–associated steatotic liver disease (MASLD) is associated with increased risk of cardiovascular disease (CVD). The MASLD vibration-controlled transient elastography (VCTE)-C cohort is designed to examine the relationships among VCTE-derived hepatic measures, coronary artery calcification, and long-term cardiovascular outcomes in patients with MASLD. Methods: This prospective, multicenter observational cohort will enroll 880 patients with VCTE-defined MASLD (controlled attenuation parameter [CAP] ≥248 dB/m) across 11 tertiary hospitals in the Republic of Korea. Additional eligibility criteria include at least one of the following: (i) type 2 diabetes; (ii) prediabetes; or (iii) obesity accompanied by at least one additional cardiovascular risk factor. Baseline assessments include noninvasive surrogates for liver fibrosis (fibrosis-4 index and liver stiffness measurement by VCTE) and steatosis (CAP by VCTE), coronary artery calcium scoring by noncontrast cardiac computed tomography, cardiometabolic profiling, and 10-year cardiovascular risk estimation primarily using the PREVENT equations, with the Pooled Cohort Equations and K-CVD model applied as complementary tools. Outcomes: The primary outcome is time to the first occurrence of a four-component major adverse cardiovascular event, comprising acute myocardial infarction, stroke, cardiovascular death, or coronary revascularization. Secondary outcomes include other cardiovascular events, hepatic and renal outcomes, extrahepatic malignancy, and all-cause mortality. Participants will be followed for up to 10 years with serial VCTE; repeat coronary artery calcium scoring is planned at 5 and 10 years in eligible participants. Conclusion: The MASLD VCTE-C cohort is expected to provide prospective evidence on liver–cardiovascular relationships that may inform integrated risk assessment in patients with MASLD. (KCT0012473).
SN - 1664-2392
ER -